Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1

FASEB Journal

Volumn 27, Issue 3, 2013, Pages 1203-1213

  Chong, Huihui ^a   Yao, Xue ^a   Qiu, Zonglin ^a   Sun, Jianping ^a   Zhang, Meng ^a   Waltersperger, Sandro ^b   Wang, Meitian ^b   Liu, Shan Lu ^c   Cui, Sheng ^a   He, Yuxian ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c University of Missouri   (United States)

Author keywords

Crystal structure; M T hook

Indexed keywords

ANTIVIRUS AGENT; C PEPTIDE; ENFUVIRTIDE; MT SC22EK; SIFUVIRTIDE; TIFUVIRTIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL FUSION; CIRCULAR DICHROISM; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROPHOBICITY; IC 50; MICROBIAL DIVERSITY; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY; THERMOSTABILITY;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84874591896     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-222547     Document Type: Article

References (44)

1. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U. S. A. 89, 10537-10541
2. Jiang, S., Lin, K., Strick, N., and Neurath, A. R. (1993) HIV-1 inhibition by a peptide. Nature 365, 113
3. Wild, C., Greenwell, T., and Matthews, T. (1993) A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051-1053
4. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U. S. A. 91, 9770-9774 (Pubitemid 24311889)
5. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (Pubitemid 27199898)
6. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 94, 12303-12308 (Pubitemid 27492523)
7. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (Pubitemid 27227210)
8. Chan, D. C., and Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684 (Pubitemid 28257575)
9. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810 (Pubitemid 32662225)
10. Colman, P. M., and Lawrence, M. C. (2003) The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4, 309-319 (Pubitemid 36383957)
11. Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 95, 15613-15617 (Pubitemid 29018748)
12. Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., Matthews, T., Johnson, M. R., Nowak, M. A., Shaw, G. M., and Saag, M. S. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4, 1302-1307 (Pubitemid 28512112)
13. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993 (Pubitemid 28116876)
14. Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., Jr., Chung, J., DeMasi, R., Donatacci, L., Drobnes, C., Delehanty, J., and Salgo, M. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (Pubitemid 36618128)
15. Lalezari, J. P., Bellos, N. C., Sathasivam, K., Richmond, G. J., Cohen, C. J., Myers, R. A., Jr., Henry, D. H., Raskino, C., Melby, T., Murchison, H., Zhang, Y., Spence, R., Greenberg, M. L., Demasi, R. A., and Miralles, G. D. (2005) T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J. Infect. Dis. 191, 1155-1163 (Pubitemid 40404375)
16. Eggink, D., Baldwin, C. E., Deng, Y., Langedijk, J. P., Lu, M., Sanders, R. W., and Berkhout, B. (2008) Selection of T1249-resistant human immunodeficiency virus type 1 variants. J. Virol. 82, 6678-6688 (Pubitemid 351875144)
17. Naider, F., and Anglister, J. (2009) Peptides in the treatment of AIDS. Curr. Opin. Struct. Biol. 19, 473-482
18. Eggink, D., Berkhout, B., and Sanders, R. W. (2010) Inhibition of HIV-1 by fusion inhibitors. Curr. Pharm. Des. 16, 3716-3728
19. Steffen, I., and Pohlmann, S. (2010) Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr. Pharm. Des. 16, 1143-1158
20. Berkhout, B., Eggink, D., and Sanders, R. W. (2012) Is there a future for antiviral fusion inhibitors? Curr. Opin. Virol. 2, 50-59
21. Otaka, A., Nakamura, M., Nameki, D., Kodama, E., Uchiyama, S., Nakamura, S., Nakano, H., Tamamura, H., Kobayashi, Y., Matsuoka, M., and Fujii, N. (2002) Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew. Chem. Int. Ed. Engl. 41, 2937-2940
22. He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., and Zhang, L. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283, 11126-11134
23. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U. S. A. 104, 12772-12777 (Pubitemid 47255230)
24. Naito, T., Izumi, K., Kodama, E., Sakagami, Y., Kajiwara, K., Nishikawa, H., Watanabe, K., Sarafianos, S. G., Oishi, S., Fujii, N., and Matsuoka, M. (2009) SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob. Agents Chemother. 53, 1013-1018
25. Nishikawa, H., Oishi, S., Fujita, M., Watanabe, K., Tokiwa, R., Ohno, H., Kodama, E., Izumi, K., Kajiwara, K., Naitoh, T., Matsuoka, M., Otaka, A., and Fujii, N. (2008) Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorg. Med. Chem. 16, 9184-9187
26. Chong, H., Yao, X., Qiu, Z., Qin, B., Han, R., Waltersperger, S., Wang, M., Cui, S., and He, Y. (2012) Discovery of critical residues for viral entry and inhibition through structural insight of HIV-1 fusion inhibitor CP621-652. J. Biol. Chem. 287, 20281-20289
27. Chong, H., Yao, X., Sun, J., Qiu, Z., Zhang, M., Waltersperger, S., Wang, M., Cui, S., and He, Y. (2012) The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J. Biol. Chem. 287, 34558-34568
28. He, Y., Cheng, J., Lu, H., Li, J., Hu, J., Qi, Z., Liu, Z., Jiang, S., and Dai, Q. (2008) Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A. 105, 16332-16337
29. Yao, X., Chong, H., Zhang, C., Waltersperger, S., Wang, M., Cui, S., and He, Y. (2012) Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J. Biol. Chem. 287, 6788-6796
30. Reeves, J. D., Lee, F. H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., and Doms, R. W. (2005) Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79, 4991-4999 (Pubitemid 40464249)
31. Stoddart, C. A., Nault, G., Galkina, S. A., Thibaudeau, K., Bakis, P., Bousquet-Gagnon, N., Robitaille, M., Bellomo, M., Paradis, V., Liscourt, P., Lobach, A., Rivard, M. E., Ptak, R. G., Mankowski, M. K., Bridon, D., and Quraishi, O. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J. Biol. Chem. 283, 34045-34052
32. Xie, D., Yao, C., Wang, L., Min, W., Xu, J., Xiao, J., Huang, M., Chen, B., Liu, B., Li, X., and Jiang, H. (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob. Agents Chemother. 54, 191-196
33. Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y. J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T. J., Moore, J. P., Miller, M. D., and Pessi, A. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A. 106, 5801-5806
34. Wexler-Cohen, Y., Ashkenazi, A., Viard, M., Blumenthal, R., and Shai, Y. (2010) Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J. 24, 4196-4202
35. Jin, B. S., Ryu, J. R., Ahn, K., and Yu, Y. G. (2000) Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1. AIDS Res. Human Retroviruses 16, 1797-1804
36. Sia, S. K., Carr, P. A., Cochran, A. G., Malashkevich, V. N., and Kim, P. S. (2002) Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. U. S. A. 99, 14664-14669 (Pubitemid 35334541)
37. He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., and Dai, Q. (2008) Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol. 82, 6349-6358 (Pubitemid 351875113)
38. Ashkenazi, A., Wexler-Cohen, Y., and Shai, Y. (2011) Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim. Biophys. Acta 1808, 2352-2358
39. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappes, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905 (Pubitemid 34535213)
40. Greenberg, M. L., and Cammack, N. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340 (Pubitemid 39177450)
41. Shimura, K., Nameki, D., Kajiwara, K., Watanabe, K., Sakagami, Y., Oishi, S., Fujii, N., Matsuoka, M., Sarafianos, S. G., and Kodama, E. N. (2010) Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors. J. Biol. Chem. 285, 39471-39480
42. Eggink, D., Bontjer, I., Langedijk, J. P., Berkhout, B., and Sanders, R. W. (2011) Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J. Virol. 85, 10785-10797
43. Liu, Z., Shan, M., Li, L., Lu, L., Meng, S., Chen, C., He, Y., Jiang, S., and Zhang, L. (2011) In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 286, 3277-3287
44. Chong, H., Yao, X., Zhang, C., Cai, L., Cui, S., Wang, Y., and He, Y. (2012) Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 7, e32599